{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:00Z","timestamp":1794018540819,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.critrevonc.2021.103504","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T02:18:00Z","timestamp":1634609880000},"page":"103504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-866X","authenticated-orcid":false,"given":"Szabolcs","family":"Kiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Gede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-5251","authenticated-orcid":false,"given":"Alexandra","family":"So\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4977-1079","authenticated-orcid":false,"given":"Bettina","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0175-7462","authenticated-orcid":false,"given":"Marcell","family":"Imrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Czibere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5349-6527","authenticated-orcid":false,"given":"Nelli","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-5658","authenticated-orcid":false,"given":"Lilla","family":"Han\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-941X","authenticated-orcid":false,"given":"Zsolt","family":"Szak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-8427","authenticated-orcid":false,"given":"B\u00e1lint","family":"Er\u00f6ss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-487X","authenticated-orcid":false,"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103504_bib0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0010","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3324\/haematol.2018.206912","article-title":"Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis","volume":"104","author":"Blommestein","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103504_bib0015","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3324\/haematol.2019.226407","article-title":"Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial","volume":"105","author":"Bringhen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000375392","article-title":"Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data","volume":"38","author":"Cartier","year":"2015","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0025","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0040","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0050","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0055","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"issue":"103","key":"10.1016\/j.critrevonc.2021.103504_bib0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0065","first-page":"58","volume":"19","author":"Firth","year":"2019"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1040-8428(01)00102-0","article-title":"Cancer epidemiology in the elderly","volume":"39","author":"Franceschi","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","article-title":"Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction","volume":"137","author":"Fraz","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/ejh.13407","article-title":"Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients","volume":"105","author":"Gil-Sierra","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103504_bib0085","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jgo.2020.05.013","article-title":"Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: a systematic review and meta-analysis","volume":"11","author":"Giri","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2004.05186.x","article-title":"Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma","volume":"127","author":"Hernandez","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0095","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0. Chapter 8: Assessing Risk of Bias in a Randomized Trial","author":"Higgins","year":"2021"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0100","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00277-015-2537-2","article-title":"Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible","volume":"95","author":"Hungria","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.16945","article-title":"Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial","volume":"192","author":"Jackson","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12185-019-02757-0","article-title":"Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan","volume":"111","author":"Kubo","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0120","doi-asserted-by":"crossref","first-page":"A617","DOI":"10.1016\/j.jval.2014.08.2179","article-title":"First-line therapy for patients with multiple myeloma: direct and indirect comparison of treatment regimens on the existing market","volume":"17","author":"Kuhr","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0125","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0130","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/OTT.S123680","article-title":"Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials","volume":"10","author":"Liu","year":"2017","journal-title":"Onco. Ther."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0140","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0145","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0150","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjh.16878","article-title":"Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)","volume":"192","author":"Maruyama","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0155","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/asheducation-2013.1.488","article-title":"How should we treat newly diagnosed multiple myeloma patients?","volume":"2013","author":"Mateos","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0160","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0170","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0175","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0180","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0185","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0190","doi-asserted-by":"crossref","first-page":"8039-","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","article-title":"Continued improvement in survival in multiple myeloma (MM) including high-risk patients","volume":"37","author":"Nandakumar","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0195","series-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Multiple Myeloma Version 4.2020","author":"NCCN","year":"2020"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0200","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0205","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0210","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0215","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0220","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0225","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0230","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0235","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0959-8049(94)00452-B","article-title":"A comparison of polychemotherapy and melphalan\/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group","volume":"31A","author":"Peest","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0240","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"Ponisch","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0245","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-021-00490-8","article-title":"Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial","volume":"11","author":"Puig","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0255","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0265","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0275","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0280","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0285","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2011.584006","article-title":"A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant","volume":"52","author":"Sacchi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0290","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0295","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0300","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2019.07.001","article-title":"Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: a systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials","volume":"143","author":"Sekine","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0305","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0310","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0315","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12185-019-02700-3","volume":"110","author":"Suzuki","year":"2019","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0320","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0325","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0330","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","article-title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","volume":"58","author":"Weisel","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0340","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0345","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1040-8428(97)10030-0","article-title":"Multiple myeloma","volume":"27","author":"Zulian","year":"1998","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103504_bib0355","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103504_bib0360","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3324\/haematol.2019.240374","volume":"105","author":"Zweegman","year":"2020","journal-title":"Haematologica"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:56:11Z","timestamp":1778518571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821002912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":72,"alternative-id":["S1040842821002912"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103504","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103504"}}